Sapidyne Instruments Inc.

Thank you to everyone that attended our KinExA Seminar at Boise State last week! We had amazing speakers, interactive learning and of course, some fun! Can't wait for the next one!

"Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory responses following tissue damage or infection and is a promising target for treatment of inflammatory disease. Here, we describe the identification of tozorakimab (MEDI3506), a potent, human anti-IL-33 monoclonal antibody, which can inhibit reduced IL-33 (IL-33red) and oxidized IL-33 (IL-33ox) activities through distinct serum-stimulated 2 (ST2) and receptor for advanced glycation end products - epidermal growth factor receptor (RAGE-EGFR complex) signalling pathways."..
"To gain an understanding of the binding kinetics and affinity required for a therapeutically effective anti-IL-33 antibody, we first determined the binding kinetics of IL-33 to sST2. The affinity of IL-33red for sST2 was 0.09 pM (95% confidence interval [CI], 0.05–0.15; Fig. 1a–c), which was determined using a highly sensitive kinetic exclusion assay (KinExA) [35]. "

Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory responses following tissue damage or infection and is a promising target for treatment of inflammatory disease. Here, we describe the identification of tozorakimab (MEDI3506), a potent, human anti-IL-33 monoclonal ant...

https://academic.oup.com/ecco-jcc/article/17/Supplement_1/i634/7009831

P504 Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells AbstractBackground. Monoclonal antibodies targeting the interleukin (IL)-23p19 subunit are effective in the treatment of inflammatory bowel diseases (IBD), but

KinExA is a technique for measuring unmodified molecules with either both molecules in solution or with one in solution and the other expressed on a cell surface. This document describes the advantages KinExA has over other biosensor technologies.

The KinExA Advantage A comparison of biosensors for Kd analysis